TP63 and neoplasm: This study reveals a central regulator of anti-tumor immunity in SCC tumors, provides a potential strategy to turn “immune-cold” SCC tumors into “hot” ones, and suggests TP63 as a candidate biomarker of immune-cold tumor for predicting immunotherapy outcome in SCC patients.